13,266 Shares in AbbVie Inc. $ABBV Acquired by Stonebridge Wealth Management LLC

Stonebridge Wealth Management LLC bought a new stake in AbbVie Inc. (NYSE:ABBV) during the second quarter, Holdings Channel.com reports. The fund bought 13,266 shares of the company’s stock, valued at approximately $2,462,000. AbbVie makes up about 2.4% of Stonebridge Wealth Management LLC’s portfolio, making the stock its 12th largest position.

Several other hedge funds also recently made changes to their positions in ABBV. TD Capital Management LLC boosted its position in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the second quarter valued at approximately $25,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. increased its holdings in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ABBV shares. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday. Bank of America upped their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Piper Sandler reiterated an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $244.55.

AbbVie Stock Performance

NYSE:ABBV opened at $223.45 on Monday. The firm’s 50 day moving average is $227.25 and its two-hundred day moving average is $209.95. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The company has a market cap of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.